Dr. Lattanzi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6204 Balcones Dr
Austin, TX 78731Phone+1 512-427-9400Fax+1 512-342-2723
Summary
- Genitourinary Medical Oncology & Clinical Trials
Education & Training
NYU Grossman School of MedicineResidency, Internal Medicine, 2016 - 2019- New York University School of MedicineClass of 2016
Certifications & Licensure
TX State Medical License 2022 - 2025
NC State Medical License 2022 - 2023
NY State Medical License 2019 - 2022- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 7 citationsClinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.Brendan J Guercio, Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Duzgol
Clinical Cancer Research. 2023-11-14 - Reply to S. Zhang.Michael Lattanzi, Samuel A Funt, Jonathan E Rosenberg
Journal of Clinical Oncology. 2022-08-10 - 30 citationsNeoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.Samuel A Funt, Michael Lattanzi, Karissa Whiting, Hikmat Al-Ahmadie, Colleen Quinlan
Journal of Clinical Oncology. 2022-04-20
Press Mentions
ESMO 2019: TROPHY-U-01: Initial Results of a Phase 2 Open-Label Study of Sacituzumab Givotecan in Patients with Metastatic Urothelial Cancer After Failure of Platinum-Based Regimens or ImmunotherapySeptember 29th, 2019- ESMO 2019: Single Agent Immune Therapy and Immune CombinationsOctober 1st, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
